Application In Synthesis of Methyl 4-fluoro-3-nitrobenzoateIn 2017 ,《Discovery of a First-in-Class Receptor Interacting Protein 1 (RIP1) Kinase Specific Clinical Candidate (GSK2982772) for the Treatment of Inflammatory Diseases》 was published in Journal of Medicinal Chemistry. The article was written by Harris, Philip A.; Berger, Scott B.; Jeong, Jae U.; Nagilla, Rakesh; Bandyopadhyay, Deepak; Campobasso, Nino; Capriotti, Carol A.; Cox, Julie A.; Dare, Lauren; Dong, Xiaoyang; Eidam, Patrick M.; Finger, Joshua N.; Hoffman, Sandra J.; Kang, James; Kasparcova, Viera; King, Bryan W.; Lehr, Ruth; Lan, Yunfeng; Leister, Lara K.; Lich, John D.; MacDonald, Thomas T.; Miller, Nathan A.; Ouellette, Michael T.; Pao, Christina S.; Rahman, Attiq; Reilly, Michael A.; Rendina, Alan R.; Rivera, Elizabeth J.; Schaeffer, Michelle C.; Sehon, Clark A.; Singhaus, Robert R.; Sun, Helen H.; Swift, Barbara A.; Totoritis, Rachel D.; Vossenkamper, Anna; Ward, Paris; Wisnoski, David D.; Zhang, Daohua; Marquis, Robert W.; Gough, Peter J.; Bertin, John. The article contains the following contents:
RIP1 regulates necroptosis and inflammation and may play an important role in contributing to a variety of human pathologies, including immune-mediated inflammatory diseases. Small-mol. inhibitors of RIP1 kinase that are suitable for advancement into the clinic have yet to be described. Herein, the authors report the lead optimization of a benzoxazepinone hit from a DNA-encoded library and the discovery and profile of clin. candidate GSK2982772 (compound I), currently in phase 2a clin. studies for psoriasis, rheumatoid arthritis, and ulcerative colitis. Compound I potently binds to RIP1 with exquisite kinase specificity and has excellent activity in blocking many TNF-dependent cellular responses. Highlighting its potential as a novel anti-inflammatory agent, the inhibitor was also able to reduce spontaneous production of cytokines from human ulcerative colitis explants. The highly favorable physicochem. and ADMET properties of I, combined with high potency, led to a predicted low oral dose in humans. In the experiment, the researchers used Methyl 4-fluoro-3-nitrobenzoate(cas: 329-59-9Application In Synthesis of Methyl 4-fluoro-3-nitrobenzoate)
Methyl 4-fluoro-3-nitrobenzoate(cas: 329-59-9) belongs to methyl benzoate. Methyl benzoate reacts at both the ring and the ester, depending on the substrate. Electrophiles attack the ring, illustrated by acid-catalysed nitration with nitric acid to give methyl 3-nitrobenzoate.Application In Synthesis of Methyl 4-fluoro-3-nitrobenzoate
Referemce:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics